君实生物
TopAlliance

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Resolutions of the Sixth Meeting of the Third Session of the Board of Directors" published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 16 December 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng and Mr. Li Cong as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* *For identification purpose only*

Stock code: 688180 Stock abbreviation: Junshi Bio Announcement No.: Lin 2021-092

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on Resolutions of the Sixth Meeting of the Third Session of the Board of Directors

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading statement or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

I. Convening of the Meeting of the Board of Directors

Shanghai Junshi Biosciences Co., Ltd.* (hereinafter referred to as the "Company") convened, by means of voting at the site meeting and via correspondence, the sixth meeting of the third session of the board of directors at the conference room of the Company on 16 December 2021. The notice of such meeting was dispatched by post to all directors on 10 December 2021. The meeting was chaired by the chairman, Mr. Xiong Jun. 14 directors were eligible to attend the meeting, and 14 directors attended the meeting. The procedures for convening and holding such meeting were in compliance with the relevant regulations of the "Company Law of the People's Republic of China" and the "Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*", and the resolutions passed thereat were legal and valid.

II. Consideration of Resolutions at the Meeting of the Board of Directors

(I) "Proposal on Capital Increase of Wholly-owned Subsidiary" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution is not required to be submitted to the general meeting of the Company for consideration.

For details, please refer to the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(II) "Proposal on the Application for Increasing Bank Comprehensive Credit Lines" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution is not required to be submitted to the general meeting of the Company for consideration.

(III) "Proposal on the Fulfillment of Exercise Conditions for the Third Exercise Period under the 2018 Share Option Incentive Scheme" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution is not required to be submitted to the general meeting of the Company for consideration.

For details, please refer to the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

The independent non-executive directors expressed independent opinions of consent on such matter, and for details, please refer to the "Independent Opinions of Independent Non-executive Directors on the Relevant Matters of the Sixth Meeting of the Third Session of the Board of Directors" disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(IV) "Proposal on Adjusting Members of Special Committees of the Board of Directors of the Company" was considered and approved

As the appointment of independent non-executive director has been considered and approved at the 2021 first extraordinary general meeting on 16 December 2021, in accordance with the requirements under the working rules for each special committees under the board of the Company, the Company made adjustments to the members of the special committees under the third session of the board accordingly.

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution is not required to be submitted to the general meeting of the Company for consideration.

This announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
17 December 2021

** For identification purpose only*